Peramivir: an intravenous neuraminidase inhibitor.

@article{McLaughlin2015PeramivirAI,
  title={Peramivir: an intravenous neuraminidase inhibitor.},
  author={Milena M McLaughlin and Erik W Skoglund and Michael G Ison},
  journal={Expert opinion on pharmacotherapy},
  year={2015},
  volume={16 12},
  pages={
          1889-900
        }
}
INTRODUCTION Peramivir (BCX-1812, RWJ-270201) is a highly selective inhibitor of influenza A and B neuraminidase that has recently been approved in the USA by the FDA to treat acute, uncomplicated influenza in adults. AREAS COVERED This review examines the discovery and development of peramavir as well as its role in the treatment of influenza. Peramivir is currently the only FDA-approved anti-influenza agent that can be given as an intravenous injection, granting it a unique role in therapy… CONTINUE READING
BETA

Similar Papers

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

In Vitro Evaluation of Absorption Characteristics of Peramivir for Oral Delivery

  • European Journal of Drug Metabolism and Pharmacokinetics
  • 2016
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Influenza H1N1 infection in immunocompromised host: A concise review

  • Lung India : official organ of Indian Chest Society
  • 2019
VIEW 2 EXCERPTS
CITES BACKGROUND & METHODS